NASDAQ · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · SMALL CAP
C4 Therapeutics, Inc. CCCC
7 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$35.9M
▲ 1.0% vs FY2024
EPS · FY25
$-1.27
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-44.4%
Net margin · FY25
-292.1%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 35.9M
Revenue, FY2025 · full 7-year series below
Revenue
Net income
The company lost 292 cents on every revenue dollar this year.
Per share
USD -1.27
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-44.4%
Return on equity, FY2025
ROE
Operating margin-320.5%
Net margin-292.1%
Return on assets-29.6%
Each USD of equity lost 44 cents this year.
Returned to shareholders
USD 86,000.00
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacksUSD 86,000.00
Share of profit-0.1%
Consecutive raises—
USD 86,000.00 in buybacks went back to shareholders in a year without profit.
Growth
—
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+5.0%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.10B
Shares outstanding, FY2025
Change, 5 years+125.1%
Change, 10 years—
The share count grew 125% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 359.1M
total assets, end of FY2025
Total assetsUSD 359.1M
EquityUSD 256.6M
CashUSD 74.6M
Current ratio7.81×
Equity funds 71% of total assets.
History
7 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
Revenue $B
0.0
0.0
0.0
0.0
0.0
·
·
Operating income $B
−0.1
−0.1
−0.1
−0.1
−0.1
−0.1
−0.0
EBITDA $B
−0.1
−0.1
−0.1
−0.1
−0.1
−0.1
−0.0
Income tax $B
0.0
0.0
0.0
0.0
0.0
−0.0
0.0
Net income $B
−0.1
−0.1
−0.1
−0.1
−0.1
−0.1
−0.0
EPS, diluted $
−1.27
−1.52
−2.67
−2.62
−1.82
−5.83
−31.03
Dividend / sh $
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
ROE %
−44.4
−45.6
−49.5
−37.8
−25.0
−78.6
·
Shares out B
0.10
0.07
0.06
0.05
0.05
0.04
0.00
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
21 of 21
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed